Interlenkin 5 (IL-5) is the main factor that promotes the terminal differentiation of eosinophil progenitors (as indicated by colony formation assays), and enhances the effector capacity of mature eosinophils. IL-5 is produced by T lymphocytes, CD4-/CD8-and mast cells and recently, messenger (m)RNA of this cytokine has been identified in eosinophils from patients with coeliac disease, asthma, or eosinophilic heart diseases. In this study, IL-5 mRNA and immunoreactive IL-5 protein were detected in tissue and blood eosinophils from patients with eosinophilic cystitis or hypereosinophilic syndromes but not in Crohn's disease. By electron microscopy associated to immunogold staining, immunoreactive IL-5 was identified in eosinophilic granules. After stimulation with IgA-, IgE-, or IgG-immune complexes, blood eosinophils were shown, by immunocytochemistry and by enzyme-linked immunosorbent assay, to secrete IL-5. These observations demonstrate that eosinophils, under physiological stimulation, can release significant amounts of IL-5, which may contribute to local eosinophil recruitment and activation.
T lymphocytes play a central role in eosinophil production, differentiation, and function through the release of soluble mediators. A number of cytokines with selective action on eosinophils has been cloned and sequenced. Among those, IL-5 is the main factor that promotes the terminal differentiation of the committed eosinophil precursors (1) and that enhances the effector capacity of mature eosinophils (2) . Whereas IL-5 production by T cells has been well documented, mRNA for IL-5 also has been identified in mast cells (3) and more recently in eosinophils from patients with coeliac disease (4), as well as in alveolar eosinophils from asthmatic patients (5) or tissue eosinophils from patients with eosinophih'c heart diseases (6) . However, until now, no evidence for the subcellular localization and secretion of IL-5 protein by eosinophils was presented.
The aim of this study was to examine the presence of immunoreactive IL-5 in tissue eosinophils from patients with a massive eosinophil infiltration associated to cystitis or Crohn's disease, as well as in blood eosinophils from patients with hypereosinophilic syndromes. Immunogold staining was used to determine the subcellular localization of IL-5. Using a specific immunoenzymatic technique, the release of IL-5 was evaluated after incubation of eosinophils with various immune complexes. Our results show that immunoreactive IL-5 protein, localized in eosinophil granules, can be secreted in pharmacologically active concentrations by highly purified eosinophils. They indicate, moreover, that in vivo synthesis, as well as in vitro secretion, might differ according to the stimulus of activation of eosinophils. The release of IL-5 by eosinophils may participate to the local recruitment and activation during inflammatory diseases associated with eosinophilia.
Materials and Methods
Eosinophila. Patients with a massive eosinophil infiltration (>30%) were selected. Bladder specimens were taken from a 47-yr-old woman who had presented several episodes of severe cystitis. Peripheral eosinophil counts were 840/mm 3. Before treatment, histological examination revealed an eosinophilic cystitis.
Four patients with Crohn's disease were selected for the presence of numerous eosinophils infiltrating intestinal lesions (between 20 and 40% of the infiltrating cells), whereas blood eosinophil counts were normal.
Peripheral eosinophils were purified from the blood of six patients fulfilling the diagnostic criteria for idiopathic h~sinophilic syndrome (HES): persistent eosinophilia (>1.5 x 109/liter) for at least 6 mo, multivisceral lesions, and absence of any recognized cause of eosinophilia. The mean blood eosinophil counts were 2.8 x 109/liter with SD 1.4. By using discontinuous metrizamide gradients, hypodense eosinophils, which sediment in the lightest density, were isolated (7). After washing with HBSS, the degree of purity (90-99%) was evaluated on cytocentrifuged preparations stained with Giemsa. After centrifugation, eosinophils were resuspended in FIBSS culture medium alone, without FCS, at a concentration of 106 cells/m].
In Situ Hybridization. Bladder and intestinal specimens were immediately fined in paraformaldehyde 4% in cacodylate buffer and embedded in paraffin. In situ hybridization was performed as previously described (4) . Briefly, the eDNA for human IL-5 was subcloned into the Blue Script vector by standard techniques. Linearized plasmid was used as the template for the synthesis in vitro of a 3sS-labeled RNA probe (Amersham-Franee, Les Ullis, France) complementary to the cellular II,5 mRNA (antisense probe). RNA was also transcribed in the opposite direction and used as a negative control (sense probe). Antisense or sense probes (4,150 cpm/mm z) were hybridized with bladder and intestinal samples as previously described (4) . To inhibit nonspecific binding of 3sS, tissues were acetylated in triethanolamine 0.1 M, then in acetic anhydride 0.25 % triethanolamine for 10 min before hybridization. Further, to avoid nonspecific binding to eosinophils, prehybridization was carried out with a sohtion containing a nonradiolabeled S-UTP irrelevant probe for at least 2 h at 42~ dithiothreitol (DTY) was added to the hybridization buffer, and RNase A was used for posthybridization washings. After development of the emulsion, tissue sections were then stained with May Grfinwald Giemsa for examination by light microscopy.
Immunohistochemistry. To detect the presence of immunoreactire Ib5 in ensinophils, tissue paraffin sections or cytocentrifuged preparations of purified blood eosinophils were incubated with a mouse mAb (IgG1 isotype) directed against human IbS. This mAb (5A5) has a neutralizing effect on human IL-5, did not crossreact with mouse IbS, and has been purified on protein A-Sepharose (Van der Heyden, J., T. Tuypens, R. Devos, G. Plaetinck, Y. Guise'z, and J. Tavernier, manuscript in preparation). Bladder or intestinal sections and cytocentrifuged preparations were washed in Tris-buffered saline (TBS), and anti-IL-5 mAb was added at a final concentration of 10 #g/m1. After incubation for 45 min at room temperature, slides were briefly washed in TBS, and enzymatic complex, alkaline phosphatase anti-alkaline phosphata~ (APAAP; Dak~ Glostrap, Denmark) was added at 1:50 dilution, and developed with ASB1 phosphate substrate and neofuscin (Sigma Chemical Co., St. Louis, MO) as previously described (8) . As control, a mAb of the same isotype but with a different specificity (anti-Echinococcus granulosus) was used with the same conditions.
Immunogoid Staining. Bladder specimens were fixed in glutaraldehyde 2% in cacodyhte buffer, dehydrated, and embedded at -35~ in Lowicryl K4M. Lowicryl sections were obtained as previously described (9) . In brief, after saturation with heat-inactivated normal rabbit serum, sections were incubated overnight at 40C with anti-huraan II.~5 mAb at 50/~g/ml and diluted in TBS containing OVA (TIE-O). After washing with TBS-O and TBS, sections were transferred on 15 am gold-conjugated rabbit and-mouse IgG solution (diluted 1:30; Janssen Life Science Division, Berne, Belgium). After a 1-h incubation at room temperature, grids were washed with TBS and distilled water successively. Lowicryl sections were stained with uranyl acetate and lead citrate. As controls, two mAbs of the same isotype were used in the same conditions: EG2, which recognizes the secreted form of eosinophil cationic protein (ECP) (10) (kindly given by Dr. P. C. Tai, St. George Hospital Medical School, London, UK), was used as positive control, and anti-IgA mAb (Immunotech, Marseilh Luminy, France) was used as a negative control. The observations were made at 60 kW with a Zeiss EM 10 electron microscope.
Eosinophil Activation. Highly purified eosinophils (;>95% purity) from patients with hypereosinophilic syndromes were incubated in HBSS without serum for 24 h at 37~ and 5% COz with recombinant human IL-3 (kindly donated by Sandoz Ltd., Basel, Switzerland) and recombinant human GM-CSF, a generous gift of Dr. J. Banchereau (Schering Plough, Dardilly, France) at a final concentration of 10-9 M. Highly purified eosinophils from the six FIES patients were also incubated with serum IgA, secretory IgA (both purchased from Sigma Chemical Co.) and myeloma IgE protein (PS myeloma; a kind gift of Dr. H. L. Spiegelberg, The Scripps Research Institute, LaJoUa, CA), or with human IgG (Sigma Chemical Co.) at a final concentration of 15 #g/ml in HBSS without serum. After a 1-h incubation at +4~ and without washing, eosinophils were then stimulated at 37~ and 5% COz with the corresponding antiIgA, anti-IgE, or anti-IgG mAb (Immunotech) at a concentration of 20 I~g/ml for a period of time varying between 15 min and 18 h.
The experiments were stopped by centrifugation of the tubes at 500g for 10 min at 4~ Supernatants were collected and frozen at -20~ until the ELISA could be performed. The cell pellets were resuspended at a concentration of 0. Measurement of lL5 in Supernatants. ID5 levels were determined by F_LISA as previously described (11) . Briefly, serial dilutions of culture supernatants were incubated for two h at room temperature in microweil modules (Maxisorps; Nunc, Rosldlde, Denmark) coated with 0.5/tg/m] of the H30 rat anti-human IL-5 mAb IgG2b (provided by Dr. J. Van der FIeyden, Roche Research). After washing, 0.1/~g of a mouse monoclonal anti-human Ib5 mAb IgG1 (mAbT; kindly provided by Glaxo Group Research Ltd., Greenford, Middlesex, UK) was added. Finally, the binding of the latter mAb was revealed by horseradish peroxidase-conjugated rat anti-mouse IgG1 mAb (LO MG1-2; Experimental Immunology Unit, Uuiversit6 Catholique de Louvain, Brussds, Belgium) followed by the appropriate substrate solution. Optical densities at 450 nm were converted in pg/ml of IL-5 using a standard curve constructed with the recombinant human ID5 kindly provided by Roche Research.
Results and Discuuion
~e~ence ofIL-5 mRNA. When bladder sections Im'form~ in a patient with eosinophilic cystitis were submitted to in situ hybridization, a strong positive signal was observ~ on numerous cells with the radiolabeled IL-5 antisense RNA probe (Hg. 1 A). Intestinal sections with massive eosinophilic infiltration, performed in the four patients with Crohn's disease, were submitted to the same procedure. In contrast with bladder sections of the patient with eosinophih'c cystitis, only few ceUs showed a positive signal (Fig. 1 C) . No signal was observed with the respective control sense probes (Fig. 1, B and D).
Immunostaining with Anti-human IL-5 mAIL To further
characterize the call population involved in the synthesis of immunoreactive IL-5, immunostaining of bladder sections with anti-human IL-5 mAb was performed. Using the APAAP procedure, typical binucleated cells were positively stained (Fig. 1 E) , whereas no staining was observed with the isotype control antibody (Fig. 1 F) . Eosinophils were the only cell type with a polylobulated nucleus in these sections. A similar procedure performed on intestinal sections from patients with Crohn's disease revealed a positive immunostaining of mononuclear cells only (data not shown).
Highly purified blood eosinophils could also be positively stained with anti-IL-5, but only after priming with IL-3 and GM-CSF (Fig. 2 A) , whereas no staining was observed with medium alone or on resting eosinophils (Fig. 2 B) . These results indicate that tissue eosinophils present in eosinophilic cystitis as well as ex vivo activated blood eosinophils could translate IL-5 mRNA, whereas eosinophils in Crohn's disease could not, confirming the results of in situ hybridization. These findings confirm and extend the recently published results (4) (5) (6) showing that eosinophils can transcribe IL-5 mRNA in coeliac disease, HES, asthma, or eosinophilic heart disease. However, they suggest that IL-5 expression by eosinophils is not observed in all diseases associated with massive eosinophilic infiltration.
A careful examination of eosinophils stained with the anti-IL-5 mAb revealed a heterogeneous labeling of the cytoplasm (Fig. 2 A) , differing from the previously described immunostaining for GM-CSF (12) but resembling the intracytoplasmic staining for IL-8 (13) . These findings led us to explore the subceUular localization of IL-5 in eosinophils. in eosinophils, immunogoldstaining with anti-IL-5 mAb revealed by means of gold-labeled anti-mouse rabbit antibodies and electron microscopy was performed on bladder sections embedded in Lowicryl. As positive control, EG2, a mAb which binds to ECP, located in granule matrix, was used. As shown in Fig. 3 A, the binding of anti-IL-5 mAb was concentrated to granule matrix, similarly to EG2 staining (Fig. 3 C) . All examined eosinophils, and more than 70% of the granules were stained with the anti-human IL-5 mAb. No staining was obtained with the anti-IgA mAb used as negative control (Fig. 3 B) . Eosinophils could therefore translate IL-5 mRNA and store the IL-5 protein in their granules. No precise identification of the localization of GM-CSF was given in the published study (12) . However, the staining of eosinophil cytoplasm by the respective antibody suggested that GM-CSF localization or storage differed from IL-5. A similar granule localization has been reported for TNF-c~ in mast ceils (14) . Upon activation, eosinophils may release IL-5 more rapidly in the extracellular space, upon degranulation, without neosynthesis.
Association of lL.5 with Eosinophil Granules. To localize IL-5

Synthesis and Secretion of IL-5 after Eosinophil Acti~tion.
Since immobilized or cross-linked IgA is able to induce eosinophil degranulation (15, 16) , we looked further at whether IgA-anti-IgA immune complexes could lead to IL-5 secretion. A kinetic study revealed that after activation of blood eosinophils with IgA immune comple~s for 15 rain at 37~ a positive intracyroplasmic staining with anti-IL-5 mAb was observed (Fig. 2 C) . After 2 h of incubation, IL-5 staining was located on the periphery and the membrane of the majority of the cells, whereas few eosinophils still showed a cytoplasmic staining (Fig. 2 D) . No staining could be observed after 18 h of incubation (Fig. 2 E) . These results suggested that IL-5 could be secreted by eosinophils. To confirm this hypothesis, the secretion of IL-5 by purified blood eosinophils after activation with immune complexes, was investigated by measurement of IL-5 in supernatants.
The amounts of IL-5 were measured in the supernatants of highly purified eosinophils by the double sandwich ELISA procedure (Fig. 4) . Significant amounts of IL-5 were measured in the supernatants of eosinophils after 18 h of activation with serum or secretory IgA. IL-5 could also be secreted after IgE-or IgG-dependent activation, but with important variations, according to the eosinophil donors.
Our results indicate that ex vivo activation of eosinophils with immune complexes, and principally IgA, consistently led to synthesis and secretion of the highest amounts of IL-5. They are in agreement with previous reports showing that IgA is the more potent stimulus for the release of granule proteins such as EDN (15) , EPO, and ECP (16) . Moreover, the localization of IL-5 associated with the role of insolubilized IgA in eosinophil degranulation might explain the detection of IL-5/n coeliac disease and eosinophilic cystitis where eosinophils are dosdy linked to IgA plasma cells (17, 18) . In contrast, in coeliac disease with IgA deficiency, IL-5 was not detected in eosinophils (P. Desreumaux, personal communication) as well as in Crohn's disease, where IgM and IgG prevail (19) .
In view of our results, we suggest that a short incubation with immune complexes induced IL-5 expression, whereas upon prolonged incubation, the secretion was initiated. Evidence for translation of IL-5 mtLNA into immunoreactive IL-5 by eosinophils from patients with various diseases was obtained by immunostaining with a specific mAb to human IL-5. A kinetic study of IL-5 immunodetection after activation of eosinophils with IgA immune complexes in vitro confirmed the synthesis of IL-5 protein by eosinophils and ruled out a possible phagocytosis of exogenous IL-5. In addition, the identification of picogram amounts of IL-5 in the supernatants of highly purified eosinophils only after activation, provides evidence to support the fact that eosinophils can synthesize, store, and secrete IL-5.
Activated T ceUs remain the principal ceUular source of IL-5, but the synthesis and secretion of IL-5 by eosinophils may provide an important autocrine pathway that is involved in local eosinophil recruitment and activation. The synthesis of their own activating factors might explain the chronicity of lesions in diseases associated with massive eosinophilic infiltration.
